



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



**Impact of Direct Acting Antiviral (DAA) Agents on
hematological and hepatic statuses of patients with
chronic hemolytic anemias and chronically infected with
hepatitis C virus (HCV)**

Thesis

Submitted for partial fulfillment of Master Degree in Internal Medicine

Presented by

Ahmed Khamis mahmoud

MBBCH, Faculty of Medicine, Ain Shams University

Supervised by

Prof. Dr. Mohamed Mahmoud Moussa

Professor of Internal Medicine and Clinical Hematology

Faculty of Medicine, Ain Shams University

Prof. Dr. Osama Ashraf Ahmed

Professor of Internal Medicine and Gastroenterology

Faculty of Medicine, Ain Shams University

Dr. Amro Mohamed Sedky El-Ghammaz

Assistant Professor of Internal Medicine and Clinical Hematology

Faculty of Medicine, Ain Shams University

Dr. Inas Abdel Moaty Mohamed

Lecturer of Internal Medicine and Clinical Hematology

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

2021



**دراسة تأثير مضادات فيروس التهاب الكبد الوبائي ذات التأثير المباشر
(DAA) على الحالات الدموية والكبدية لمرضى الأنيميا التكميرية
المزمنة والمصابين بالالتهاب الفيروسي سي**

رسالة

توطئة للحصول علي درجة الماجستير في الباطنة العامة
مقدمة من

الطبيب / احمد خميس محمود

بكالوريوس الطب و الجراحة- كلية الطب جامعة عين شمس
تحت إشراف

أ.د/ محمد محمود موسى

أستاذ الباطنة العامة وأمراض الدم الإكلينيكية
كلية الطب- جامعة عين شمس

أ.د/ اسامه اشرف احمد

أستاذ الباطنة العامة والجهاز الهضمي
كلية الطب- جامعة عين شمس

د/ عمرو محمد صدقي الفماز

أستاذ مساعد الباطنة العامة وأمراض الدم الإكلينيكية
كلية الطب- جامعة عين شمس

د/ إيناس عبد المعطي محمد عيد

مدرس الباطنة العامة وأمراض الدم الإكلينيكية
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠٢١

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

My thanks first to "Allah" who give me the ability and strength to complete this work.

*I would like to express my indebtedness and deepest gratitude to **Prof. Dr. Mohamed Mahmoud Moussa**, Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University for his valuable advice, guidance and constructive criticism, also for the invaluable assistance and efforts he devoted in the supervision of this study.*

*I'll never forget, how co-operative was **Prof. Dr. Osama Ashraf Ahmed**, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, also he was encouraging all the time. It is honorable to be supervised by him.*

*I'll never forget, how co-operative was **Dr. Amro Mohamed Sedky El-Ghammaz**, Assistant Professor of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, also he was encouraging all the time. It is honorable to be supervised by him.*

*I would like also, to express my great thanks to Dr. **Inas Abdel Moaty Mohamed**, Lecturer of Internal Medicine and Clinical Hematology, and Faculty of Medicine – Ain Shams University. Her valuable advises and continuous support facilitated completing this work.*

I'd like to give my warmest appreciation to my family and my friends who always give me a great support.

I would like to thank my colleagues and everyone who made this work possible and enjoyable.

Ahmed Khamis
2021.

CONTENTS

Title	Page
• List of Table	II
• List of Figures.....	IV
• List of Abbreviations	V
• Introduction	1
• Aim of the work.....	3
• Review of literature.....	
Chapter (1): Hepatitis C Virus Infection in Egypt: Current Situation and Future Perspective	4
Chapter (2): Hemolytic Anemia	34
Chapter (3): Relation between Chronic Hemolytic Anaemia and Chronic Hepatitis CTherapy by Direct Acting Antiviral Drugs	64
• Subjects and methods	76
• Results	81
• Discussion.....	116
• Summary.....	133
• Conclusions	135
• Recommendations	136
• References	137
• الملخص العربي	150

LIST OF TABLE

Table No	Subjects	Page
Table (1):	Egypt HCV prevalence results in recent surveys	16
Table (2):	Overview of the Hemolytic Anemias	39
Table (3):	Agents that Precipitate Hemolysis in Patients with G6PD Deficiency	44
Table (4):	Level of evidence / strength of recommendation	66
Table (5):	Risk factors for ribavirin-induced haemolytic anaemia	70
Table (6):	Descriptive data of the studied groups according to demographic data	81
Table (7):	Distribution of the studied cases according to hematology diagnosis in Hemolytic anemia group	82
Table (8):	Distribution of the studied cases according to child score in Chronic liver disease group	83
Table (9):	Side effects of treatment regimen	84
Table (10):	Comparison between the studied groups according to safety of drugs	86
Table (11):	Descriptive data of Efficacy among studied cases	86
Table (12):	Comparison between the studied groups according to HCV PCR	88
Table (13):	Comparison between the studied groups according to TLC	90
Table (14):	Comparison between the studied groups according to HGB	92
Table (15):	Comparison between the studied groups according to PLT	94

List of Table

Table No	Subjects	Page
Table (16):	Comparison between the studied groups according to different parameters	96
Table (17):	Comparison between the studied groups according to Trans. Req	99
Table (18):	Comparison between the studied groups according to S. Creatinine	100
Table (19):	Comparison between the studied groups according to ALT	102
Table (20):	Comparison between the studied groups according to AST	104
Table (21):	Comparison between the studied groups according to bilirubin.....	106
Table (22):	Comparison between the studied groups according to I.Bilirubin	108
Table (23):	Comparison between the studied groups according to albumin	110
Table (24):	Comparison between the studied groups according to INR	112
Table (25):	Comparison between the studied groups according to AFP.....	114

LIST OF FIGURES

Figure No	Subjects	Page
Figure (1):	HCV: model structure and genome organization. Notes:.....	5
Figure (2):	Algorithm for the evaluation of hemolytic anemia.....	38
Figure (3):	Schistocytes (arrows).....	42
Figure (4):	Target cells (arrows).....	46
Figure (5):	Distribution of the studied cases according to sex.....	81
Figure (6):	Distribution of the studied cases according to hematology diagnosis in Hemolytic anemia group.	82
Figure (7):	Distribution of the studied cases according to treatment status in Hemolytic anemia group.	83
Figure (8):	Descriptive data of Side effects in Hemolytic anemia group.....	85
Figure (9):	Descriptive data of Side effects in Chronic liver disease group.	85
Figure (10):	Descriptive data of Efficacy in Hemolytic anemia group.	87
Figure (11):	Descriptive data of Efficacy in Chronic liver disease group.	87
Figure (12):	Comparison between the studied groups according to HCV PC.	89
Figure (13):	Comparison between the studied groups according to Liver size.....	97
Figure (14):	Comparison between the studied groups according to Liver consistency.	97
Figure (15):	Comparison between the studied groups according to Spleen.....	98

LIST OF ABBREVIATIONS

Abb. : Full term	
AFP	: Alpha Fetoprotein
AIHA	: Autoimmune hemolytic anemia
ALT	: Alanine Transaminase
AST	: Aspartate Transaminase
ATP	: Adenosine triphosphate
CBC	: Complete blood count
CHC	: Chronic hepatitis C
CS	: Caesarean section
CTL	: Cytotoxic T lymphocytes
DAAs	: Direct acting antivirals
DAT	: Direct antiglobulin test
DIC	: Disseminated intravascular coagulation
EDHS	: Egyptian Demographic Health Survey
EHIS	: Egyptian Health Issues Survey
ENT1	: Equilibrative nucleoside transporter 1
EPO	: Erythropoietin
G6PD	: Glucose-6-phosphate dehydrogenase
G-CSF	: Granulocyte colony-stimulating factor
Hb	: Haemoglobin
HbE	: Hemoglobin E
HBsAg	: Hepatitis B surface antigen
HBV	: Hepatitis B virus
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HIV	: Human immunodeficiency virus
HSCT	: Hematopoietic stem cell transplantation
HUS	: Hemolytic uremic syndrome

List of Abbreviations

Abb.	:	Full term
IDUs	:	ILLICIT drug users
INF	:	INTERFERON
INR	:	International Normalized Ratio
KAP	:	Knowledge, attitude and practice
LDH	:	Lactate dehydrogenase
LFTs	:	Liver Function Tests
MOC	:	Model of Care
MRR	:	Mortality rate ratios
NAAC	:	National Anaemia Action Council
NCCVH	:	National Committee for Control of Viral Hepatitis
NCI	:	National Cancer Institute
PAT	:	Parenteral antischistosomal treatment
PCR	:	Polymerase Chain Reaction
PegIFN	:	Pegylated interferon-a
PEG-IFN	:	Pegylated-interferon
PT	:	Prothrombin Time
PT/PTT	:	Prothrombin time/partial thromboplastin time
PTT	:	Partial Thromboplastin Time
QoL	:	Quality of life
RAVs	:	Resist anceassociated variants
RBV	:	Ribavirin
SCD	:	Sickle Cell Disease
SDH	:	Social determinants of health
SNP	:	Singlenucleotide polymorphism
SVR	:	Sustained virological response
TE	:	Transient Elastography
TTP	:	Thrombotic thrombocytopenic purpura
WHO	:	World Health Organization

INTRODUCTION

HCV infection is a major clinical problem in patients with chronic hemolytic anemias e.g. Thalassemia, sickle cell patients, spherocytosis (*Wonke et al., 1990*). Along with iron overload, it represents a major risk factor for the development of liver fibrosis and eventually cirrhosis in this population (*Angelucci et al., 2002*). Various studies have shown a faster progression to severe liver fibrosis in patients with concomitant HCV infection and high liver iron concentrations. The prevalence of cirrhosis in these patients ranges from 10% to 20% (*Di Marco et al., 2010*).

Although the overall survival of patients with chronic hemolytic anemias has recently increased due to improvements in iron chelation therapy and the subsequent reduction in cardiac complications, liver-related mortality and morbidity rates have risen because of liver failure and development of hepatocellular carcinoma (*Voskaridou et al., 2012*). Therefore, eradication of HCV infection has become a priority in these patients.

Until recently, the only available treatment for HCV infection was the combination of pegylated interferon-(PEG-IFN- α) and ribavirin (RBV), which showed modest efficacy in those populations (*Casu et al., 2014*). However, its use was limited by poor tolerance, several contraindications, and concerns about RBV-induced hemolysis and the subsequent increase in transfusion needs (*Alavian et al., 2010*).

More recently, IFN-free regimens, based on (DAAs), have been developed, showing greater efficacy and tolerance in patients with chronic HCV infection. According to international guidelines, patients who are transfusion dependent should be treated with these new regimens, preferably those without RBV (*European et al., 2017*).